Kirjoita osake tai kryptovaluutta hakupalkkiin saadaksesi yhteenvedon
PYC Therapeutics Ltd
PYCPYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia. Address: Harry Perkins Inst. of Medical Research, Nedlands, WA, Australia, 6009
Analytics
WallStreetin tavoitehinta
0.51 AUDP/E-suhde
–Osinkotuotto
–Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Kuluva vuosi
Edellinen vuosi
Nykyinen vuosineljännes
Viimeinen vuosineljännes
Avainluvut PYC
Osinkoanalytiikka PYC
Osinkojen kasvu 5 vuoden aikana
–Jatkuva kasvu
–Maksusuhde 5 vuoden keskiarvo
–Osinkohistoria PYC
Osakkeen arvostus PYC
Talousasiat PYC
Tuloksia | 2019 | Dynamiikka |